At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMPS COMPASS Pathways plc
Trading 12-22 15:22:02 EST
6.54
+0.17
+2.61%
High6.74Low6.30Vol614.49K
Open6.36D1 Closing6.37Amplitude6.91%
Mkt Cap627.61MTradable Cap381.82MTotal Shares96.02M
T/O4.01MT/O Rate1.05%Tradable Shares58.41M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Compass Pathways Hosts Webinar on Commercial Preparations for TRD and PTSD Clinical Trials
Reuters  ·  12-09
Compass Pathways Hosts Webinar on Commercial Preparations for TRD and PTSD Clinical Trials
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (Trd) and Clinical Trial Plans for Post-Traumatic Stress Disorder (Ptsd) on January 7, 2026, 10:00Am Et
THOMSON REUTERS  ·  12-09
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (Trd) and Clinical Trial Plans for Post-Traumatic Stress Disorder (Ptsd) on January 7, 2026, 10:00Am Et
Compass Pathways to Join Evercore and Piper Sandler Healthcare Conferences
Reuters  ·  11-20
Compass Pathways to Join Evercore and Piper Sandler Healthcare Conferences
Compass Pathways Is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  11-06
Compass Pathways Is Maintained at Overweight by Morgan Stanley
RBC Adjusts Price Target on COMPASS Pathways to $16 From $15, Maintains Outperform Rating
MT Newswires Live  ·  11-05
RBC Adjusts Price Target on COMPASS Pathways to $16 From $15, Maintains Outperform Rating
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
Reuters  ·  11-05
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
Stock Track | Compass Pathways Plunges 5.28% After Reporting Larger-Than-Expected Q3 Loss
Stock Track  ·  11-05
Stock Track | Compass Pathways Plunges 5.28% After Reporting Larger-Than-Expected Q3 Loss
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, Hertz Global, Metsera
Reuters  ·  11-04
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, Hertz Global, Metsera
Compass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  11-04
Compass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD
Reuters  ·  11-04
Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD
BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug
Reuters  ·  11-04
BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug
Biotech firm Compass Pathways' operating income beats Q3 analyst expectations
Reuters  ·  11-04
Biotech firm Compass Pathways' operating income beats Q3 analyst expectations
Stock Track | COMPASS Pathways Soars 11.60% Pre-market on Accelerated Commercialization Plans for COMP360
Stock Track  ·  11-04
Stock Track | COMPASS Pathways Soars 11.60% Pre-market on Accelerated Commercialization Plans for COMP360
Compass Pathways Q3 EPS $(1.44) Misses $(0.38) Estimate
Benzinga  ·  11-04
Compass Pathways Q3 EPS $(1.44) Misses $(0.38) Estimate
BRIEF-COMPASS Pathways Q3 EPS USD -1.44
Reuters  ·  11-04
BRIEF-COMPASS Pathways Q3 EPS USD -1.44
Compass Pathways reports Q3 2025 results with cash position of $185.9 million
Reuters  ·  11-04
Compass Pathways reports Q3 2025 results with cash position of $185.9 million
Compass Pathways: Accelerating Commercialization Readiness Plans for Comp360 by 9-12 Months
THOMSON REUTERS  ·  11-04
Compass Pathways: Accelerating Commercialization Readiness Plans for Comp360 by 9-12 Months
Compass Pathways: Disclosure of 26-Week (Part B) Comp006 Data Expected in Early Q3 2026
THOMSON REUTERS  ·  11-04
Compass Pathways: Disclosure of 26-Week (Part B) Comp006 Data Expected in Early Q3 2026
Compass Pathways Q3 Pretax Profit USD -137.947 Million
THOMSON REUTERS  ·  11-04
Compass Pathways Q3 Pretax Profit USD -137.947 Million
Press Release: Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
Dow Jones  ·  11-04
Press Release: Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Introduction

Company Name.
COMPASS Pathways plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Issue price:
--